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CONCLUSIONS: At present, there are 1469 medicines on the Slovak market includ-
ing atorvastatin, while there are only 244 with simvastatin and 6 with lovastatin as
active ingredient. The decrease in use of simavstatin might be also caused by
appearance of its associated side-effects including myopathy. Rosuvastatin pres-
ents good alternative of treatment when the effectiveness of classic statins is not
sufficient.
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OBJECTIVES: Act No. 140/1998 on Drugs and Medicinal Aids which is valid in Slo-
vakia to the november 2011, possible to apply non-compulsory generic substitution
in community pharmacies. However, according to available data, applied only in 5
to 10 percent. New Act on Drugs and Medicinal Aids (Act No. 362/2011) entered into
force from 1. december 2011, which introduced required generic prescription to
ensure adequate health care for the insured, to improve health and enhance the
quality and availability of health care in the effective use of funds. The aim is to
reduce the ever rising cost of health care. The cardiovascular disease is making the
largest share of financial costs.METHODS:Drugs expenditure derived from data of
the General Health Insurance. RESULTS: In Slovakia during the period 2009-2011
constituted the largest average share of total spending on medicines covered by the
public health insurance ATC group C, 22.7% (cardiovascular system). Despite a
decline in drug packages issued for cardiovascular disease in the last year of 3.25%,
there has been an increase in the value of the funds of 3.14% of public health
insurance. Research focused on share and impact of generic substitution made in
the Slovak pharmacies in 2010-2011 showed the most substituted products in ATC
group C (36.14%), with the most substituted drugs belong amlodipine (6.26%) and
atorvastatin (4.97%).CONCLUSIONS: In recent years, increasing the volume of pub-
lic expenditure on drugs co-payment patient is growing rapidly. The use of generic
drugs is to reduce consumption and costs for medication, not to the detriment
quality therapy. One of the aims of the new law about medicines and medical
devices to bring savings to the state and citizens in the area of drugs. Preliminary
studies suggest differences.
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BURDEN OF HYPERTENSION IN SELECTED EU COUNTRIES: 2010-2025
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OBJECTIVES: The burden of chronic diseases is an important parameter for finan-
cial resource allocation and health care system capacity planning. Future preva-
lence and distribution of chronic conditions depend on the development of popu-
lation size and structure. The European population is expected to slowly grow and
rapidly age in the next decades. Our contribution aims at evaluating the impact of
demographic change on prevalence of hypertension in Europe. The use of projec-
tions to support long-term planning of health care resources will be discussed.
METHODS: A prevalence-projection scenario was developed combining age-/sex-
specific population projections with chronic disease prevalence rates. Population
projections were taken from Eurostat statistics. Hypertension prevalence rates
were estimated from the European Healthcare Access Panel (EHP, 2008), a repre-
sentative health and health care utilization survey in five EU countries (Germany,
UK, France, Italy and Spain). The weighted sample comprised 136.397 respondents
aged 20-79. Multiplying projected population numbers with the respective age- and
sex-specific hypertension rates from 2008 provided an estimate for the number of
hypertensives by country in forthcoming years. RESULTS: As calculated from EHP
data, in 2010, 15.9M Germans aged 20 to 79 years suffered from hypertension (10.4M
in UK, 8.2M in France, 9.7M in Italy and 6.4M in Spain). For the year 2025, our model
predicts the prevalence figures to increase to 17.3M in Germany, 12.3M in UK, 9.6M
in France, 11.3M in Italy and 7.8M in Spain. For all five countries combined hyper-
tension is calculated to increase by 15.3%, from 50.6M to 58.4M. CONCLUSIONS:
The projections show a considerable increase in the prevalence of hypertension:
the total population in the five biggest EU countries will grow only by 5.7% but the
number of people with hypertension will increase by 15.3%. These data quantify
the influence of ageing on disease burden and reflect an increased need for appro-
priate health care expenditure and capacities.
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OBJECTIVES:The impact of the type of drug insurance plan on costs of medications
is not well known. We aimed to compare the costs of antidepressants and statins,
two of the most prescribed drugs, in Québec patients who are covered by private
and public drug insurance. METHODS: Two matched cohort studies were con-
ducted using prescription claims databases for Quebec residents with private
(reMed) and public drug insurance (RAMQ). Patients were aged 18 to 64 years and
filled at least one prescription for an antidepressant (Cohort 1) or a statin (Cohort 2)
in monotherapy between December 2007 and September 2009. The average
monthly costs (medication cost  dispensing fee) of antidepressants and statins
per patient and the percent cost difference for a 30-day prescription for each anti-
depressant and each statin product were compared between patients with private
and public drug insurance using t-tests and regressionn models. RESULTS: Cohort
1 included 194 privately and 1923 publicly insured patients while the correspond-
ing figures for Cohort 2 were 174 and 1712, respectively. The average cost of anti-
depressants and statins per patient per month was significantly higher among
privately-insured than publicly-insured patients [Cohort 1: $48.1725.19 vs.
$33.7217.58, p0.001; Cohort 2: $61.1922.31 vs. $54.6220.48$, p0.001]. The
cost of 30-day prescriptions for most individual drugs of antidepressants and st-
atins was significantly more expensive for privately-insured patients than
publicly-insured patients. CONCLUSIONS: Higher cost of antidepressants and st-
atins observed in privately-insured patients might be due to different pharmacy
payment requirements and the dispensing fee restrictions under the public plan.
More research is need to investigate whehter or not this higer drug cost translates
into lower patient’s adherence and persistence to medications.
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OBJECTIVES: To assess the effectiveness of an educational patient-centered pro-
gram on the reduction of Blood Pressure (BP) by a better adherence to pharmaco-
logical and non pharmacological treatment. METHODS: A randomized controlled
study including hypertensive patients (SBP135 mmHg and DBP85 mmHg) 18
years of age or older. Patients were enrolled by the Center for the Diagnosis and
Treatment of Hypertension Cardarelli Hospital and were randomly assigned to
Control group (C) and Intervention group (I ). Group I, in addition to the routine care,
received a Patient Information Leaflet giving information on hypertension and
participated to three educational group sessions (designed according to the focus
group and role playing methods), respectively at 2,4 and 9 months after the recruit-
ment. Group C received the routine care. Both groups received a control visit with
BP measure at 2, 4 and 9 months after the recruitment. The primary outcome was
the change in BP values. BP measurements were assessed according to the inter-
national guidelines. Information on patients’ demographics, co-morbidity and
drugs were collected at baseline and at 12-month-follow-up. RESULTS: A total of
627 patients were randomly assigned to the study (418 in the Group C and 209 in the
Group I). There were no significant differences (P0.05) in both groups concerning
age and gender. A greater reduction of SBP was observed in the Group I (-6.0 mmHg
14.0 vs -3.4 mmHg 11.3, P0.05 ) CONCLUSIONS: Educational patient-centered
program may be an effective strategy to improve blood pressure control, due a
better adherence to therapy and a more careful health behavior.
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OBJECTIVES: To investigate the extent to which the convenience offered by fixed-
dose combination preparations is valued by payers when performing Health Tech-
nology Assessments (HTA). METHODS: Publication lists of major European HTA
agencies (SMC, HAS, IQWiG, NICE, UVEF, AHTAPoL, TLV, CVZ) were searched man-
ually for appraisals on fixed-dose combination drugs from 2010 onwards. Of the
agencies that published assessments, the payers’ perception of fixed-dose combi-
nation regarding their potential of improving adherence was evaluated. The inves-
tigation focused on three large therapeutic areas: diabetes, hypertension, rheuma-
toid arthritis. RESULTS: We identified 135 assessments of diabetes (61),
hypertension (36), and rheumatoid arthritis (38) medications. 11 HTAs assessed
fixed-dose combination preparations. Of these, 9 HTAs, conducted by two agencies
(SMC and HAS), provided insights on adherence and ease of use. While SMC in
general recognizes the potential advantage of fixed-dose combination to reduce a
patient’s pill burden at no additional or moderately higher costs, clinical trials did
not provide any proof. Issues seen were differences in recommended dosing levels
between the normal formulations and the fixed-dose preparations, exhibiting po-
tential safety risks to be weighed against potential benefits. Likewise, HAS could
not find a benefit of fixed-dose over free dose combinations in terms of efficacy and
quality of life. In addition, HAS holds the opinion that dose combinations of more
than two drugs strongly limit individual up-titration, and may lead to over-pre-
scribing and misuse, thereby making the medical benefit insufficient for
reimbursement.CONCLUSIONS:Adherence is inversely related to the number of doses
per day, and poor adherence is the primary reason for sub-optimal clinical benefit, re-
duces patient’s quality of life and wastes health-resources. Although fixed-dose combi-
nation preparations can significantly increase patient adherence, our analysis showed
that HTA agencies would only recognize the value of fixed-dose combinations for reim-
bursement decisions if clinical proof of superior adherence was available.
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OBJECTIVES:Analyses were conducted on Republic of Srpska (RS) Health Insurance
Fund (HIF) national prescription database. Analyses explored health expenditure
differences in pharmaceutical consumption for the fiscal year 2011 versus 2010. RS
HIF provides coverage for a population of 1.2 million. METHODS: RS HIF national
prescription database was explored to determine expenditure breakdown by ther-
apeutic category and the appropriate positive list designation. Key cost drivers and
the differences between two fiscal years in each therapeutic category were identi-
fied. Positive lists A (drugs at reimbursement rate of 90%), A1 (drugs not registered
with Agency for Drug Approval required to treat certain conditions at reimburse-
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ment rate of 90%) and B (drugs at reimbursement rate of 50%) were observed.
RESULTS: In 2010, total expenditure for all prescription drugs was €36.5 million. In
2011, total expenditure for all prescription drugs was €43.2 million. Thus, there was
a cost / consumption increase of 18.23% across the board. Cardiovascular thera-
peutic area carried most of the burden in 2010 and 2011 with the above average
increase of 26.46% amounting to 31.44% of total consumption in 2011
CONCLUSIONS: Moderate increase in cost / consumption from 2010 to 2011 pre-
dominantly accounts for disease management medicines.
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OBJECTIVES:To define the factors which affect the price of single pill combinations
of antihypertensive including angiotensin receptor blockers (ARB) in Turkey and to
estimate the price of amlodipine / valsartan 10/320 mg combination (28 package).
METHODS: ARBs in single pill combination (SPC) with calcium channel blocker
(CCB) or diuretics were evaluated. The prices of the only reimbursed combinations
were abstracted from the price list of the Turkish Ministry of Health. ARB type, dose
increment regarding minimum available dose of ARB, CCB and diuretics in the
market, being original drug and package size were analyzed as predictor in a re-
gression model to estimate the price of the combination. RESULTS: In Turkey, 113
SPCs which include candesartan or eprosartan or irbesartan or losartan or olmesar-
tan or telmisartan or valsartan as ARB, and hydrochlorothiazide as diuretic or
amlodipine as CCB are currently reimbursed. The regression model showed that
ARB type, dose increment in ARB and amlodipine and package size can be used to
predict combination price (B0.89, 4.01, 12.61 and 0.87 respectively; P0.0001 for
all). Being original drug or dose increment in HCTZ have no significant effect on
price (B-0.028, P0.312; B0.001, P989, respectively). The model explains 92% of
variance in drug price. The price of the amlodipine / valsartan 10/320 mg (28 pack-
age) is estimated to be 55.91 TL (24.59 Euro) (95% CI 52.46 – 59.12 TL) by using the
formula. CONCLUSIONS: The formula can be used for estimating the price of the
new SPC, when ARB type, ARB and amlodipine – if used in combination-, package
size are known. Interestingly neither adding HCTZ nor being original drug affect
price of the antihypertensive SPCs in Turkey.
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OBJECTIVES: To describe primary care (PC) physicians’ attitudes towards their
health and work in order to segment them in typological groups, and to establish
the relationship between self-perceived cardiovascular (CV) health of physicians
with the recommendations to their patients. METHODS: Cross-sectional study,
through a survey, on PC physicians in Spain. Data on socio-demographic, self-
perceived CV risk and self-assessed consistency between recommendations and
personal practice were collected. The attitude of physicians was estimated based
on the degree of agreement to a set of given phrases. A cluster analysis was per-
formed to identify population segments. RESULTS:A total of 2,583 physicians were
recruited (53.4% women, meanSD age 44.99.3 years), 77.6% of them had 10
years of professional experience. 76.6% perceived their current CV risk as low,
19.9% moderate and 3.5% high. The different physicians’ attitudes clustered them
into two general groups and five subgroups: 40% of physicians were classified as
proactive and close to their patients (24% of them were seeing by the patients as an
example, and 16% were strongly motivated and responsible), and 60% were
grouped as distant and sceptical (20% reserved and distant, without influence of
professional experience in self-care, 20% self-critical, sceptical that their knowl-
edge and health may influence their patients, and 20% unmotivated and critical
with the system). 76.6% of physicians considered to be fairly or completely consis-
tent between what they did and what they recommended to their patients. Twen-
ty-four percent of physicians with more years of experience were completely con-
sistent vs. 18.7% with less experience (p0.01). By gender, 24.3% of men were
completely consistent vs. 21.6% of women (p0.05). CONCLUSIONS: Only four out
of ten physicians were close to their patients and eight considered having a low CV
risk and declared to be consistent between what they do and what they recom-
mend to their patients.
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OBJECTIVES: Hypertension is an established risk factor of cardiovascular disease.
However, its impact on disability-free life expectancy (DFLE) is not well known,
especially in Japan, which has the top-ranked life expectancy worldwide.
METHODS: NIPPON DATA80 and NIPPON DATA90 were two nationwide cohort
studies conducted in Japan, in which participants came from random-sample sur-
veys in the years 1980 and 1990. The DFLE of each hypertension group at the age of
60 years was calculated using the Sullivan method. This estimation was based on
age-specific mortality rates of each hypertension group, estimated by Poisson re-
gression using NIPPON DATA80, and the disability prevalence of each hypertension
group, estimated by logistic regression using NIPPON DATA90. To consider the
effect of smoking on DFLE, we set conditions on the smoking status in the regres-
sion model. The blood pressure at baseline was used to categorize hypertension
(mmHg, systolic blood pressure/diastolic blood pressure): optimal (120/80), pre-
hypertension (120–139/80–89), hypertension I (140–159/90–99), and hypertension
II (160/100). The disability prevalence was measured by the Katz activity of daily
living scale. RESULTS: Among men/women who never smoked, DFLE (years) at age
60 was 21.1/21.9 for optimal hypertension, 20.9/21.6 for prehypertension, 19.8/20.8
for hypertension I, and 18.9/20.1 for hypertension II. This consistent decrease in
hypertension grade was also observed in men and women who were currently
smoking: DFLE (years) at age 60 was 19.0/21.0 (optimal), 18.7/20.7 (prehyperten-
sion), 17.6/19.9 (hypertension I), and 16.6/19.1 (hypertension II). CONCLUSIONS: In
Japan, DFLE decreases as hypertension grade increases. A strategy for reducing
hypertension is recommended to expand the DFLE in Japan.
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OBJECTIVES: To evaluate venous thromboembolism (VTE) prophylaxis pattern for
total knee arthroplasty (TKA) and total hip arthroplasty (THA) in the context of
Brazilian health care system.METHODS: Retrospective medical chart review study
of patients undergoing elective TKA or THA in 2010. All charts were from either one
public or two private hospitals in São Paulo, Brazil. Patients were 18 years old, and
excluded from the study if antithrombotic drugs were used prior to surgery. De-
scriptive analysis was performed through frequency distributions and mean/stan-
dard deviation (SD). RESULTS: From a total of 233 patients, 215 (92.3%) were in-
cluded in the study: 121 (56.3%) TKA and 94 (43.7%) THA. Mean age was 68.2 (SD 9.8)
years and 75.2% were female in the TKA group while, in the THA group mean age
was 56.3 yrs (SD 15.6) and 53.2% were female.. From the public hospital, 71/81
(87.7%) patients received drug prophylaxis, being enoxaparin the choice of treat-
ment. Enoxaparin onset mean time was 29hs after both surgery types. Mean inpa-
tient treatment duration was 3 (TKA) and 4 days (THA). In private hospitals 132/134
(98.5%) received prophylaxis. Treatment of choice was enoxaparin in 130 (98.5%),
while dabigatran and compression stocking in one case each. Compression stock-
ing represented adjuvant prophylaxis in 16.7%. Onset mean time was 20hs after
TKA and 17hs after THA for enoxaparin while 46hs for dabigatran. Mean inpatient
treatment duration was 4 days(enoxaparin) and 3 days (dabigatran).
CONCLUSIONS: The intra-hospitalar prevention rates of VTE in this study is within
international (ENDORSE 2008), practice, while with lower rates in the public. There
are uncertainties that outpatients received the same level of VTE prophylaxis. It is
important to continue the awareness of the clinical and economic impact of VTE
after orthopedic surgery, mainly in the outpatient care.
INFECTION - Clinical Outcomes Studies
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EFFECT OF ANTITUBERCOLOSIS TREATMENT ON LEVER ENZYMES
Hadida E
NCDC, Tripoli Libya, Tripoli, Libya
Tuberculosis (TB) is one of the most common infectious diseases caused by Myco-
bacterium tuberculosis. The wide prevalence of tuberculosis all over the world
makes it social and economical burden especially for developing countries and the
use of anti tuberculous drugs is an optimistic approach for this problem.Certain
adverse reaction associated with antituberculosis use need to be properly evalu-
ated especially antituberculosis treatment induced liver injury and the
hepatotoxicity. OBJECTIVES: Assessment of the severity and frequency of liver
injury and hepatotoxicity caused by different anti-tuberculosis treatment drugs.
METHODS: Seventy five patients randomly selected from newly diagnosed TB pa-
tients referred to Abo-Seta hospital in Tripoli, Libya for treatment during period
from 1 January to 30 June. All patients received Directly Observation Treatment for
Short period (DOTS) antituberculosis regime. Blood samples for liver function tests
were obtain before starting the treatment and monthly assessment after starting
the treatment for 6 months. RESULTS: In our study the patients developed ATT
induced hepatotoxicities by increasing of all three enzymes 43.9% For alanine
amino transferase (ALT), 36.6% for AST and 44.6% for ALK. Serious liver dysfunction
in the first month compare with control sample, 36.25  1.39 U/L, after one month
increased to 64.6  3.55 U/L, n 75, (P  0.05) from the sample before treatment.
Alkaline phosphatase (ALP) shows increase after one month of treatment from
156.17  21.35 U/L, after one month 281.83  45.8 U/L, n 75, (P  .05).
CONCLUSIONS: There is significant increase in liver enzymes after starting of
DOTS regime.
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